What patients should know about testing, safety standards, and product transparency before moving forward with treatment.
Interest in regenerative medicine continues to grow as patients explore options for recovery support, joint health, healthy aging, and overall wellness. As the field has expanded, so have the number of products, treatment approaches, and clinics offering regenerative therapies.
When evaluating a regenerative therapy, many patients want to understand how a product is sourced, tested, and documented before making a treatment decision. Just as physicians review important information about traditional medical products, many clinicians also evaluate documentation, testing standards, and quality-control measures when considering biologic therapies.
Whether consulting a physician, researching companies, or investigating laboratories, there are several questions patients may wish to ask. The availability of documentation may help patients and physicians make more informed decisions.
The Foundation of Safety: Laboratory Standards
The origin of a biological product determines its safety. The first detail a consumer must verify is the facility where the therapy is processed.
Patients should explicitly ask whether a product is manufactured in an FDA-registered laboratory and what quality-control standards are followed during production. FDA registration is one factor many clinicians consider when evaluating manufacturing standards. Products manufactured in FDA-registered facilities are produced under established quality-control processes and are subject to regulatory oversight at the place of manufacture.[1, 3]
Patients should also ask whether the product includes lot numbers, QC identification numbers, donor traceability information, and independent testing documentation. These records help physicians verify product sourcing, testing, and manufacturing consistency.[2]
In addition to product traceability, patients may wish to understand how the product is tested. Internal testing by the manufacturer provides valuable information, but many clinicians also look for independent third-party validation. One question patients can ask is whether testing was performed by a third-party, CLIA-registered independent laboratory. CLIA (Clinical Laboratory Improvement Amendments) certification means the laboratory meets strict federal quality standards for clinical testing, helping to ensure that reported safety and content data are generated through objective testing processes.[3]
Why Transparency Matters
Regenerative medicine includes a wide range of products and treatment philosophies. While no single checklist can determine whether a therapy is appropriate for every patient, understanding how a product is sourced, tested, and documented can support more informed conversations with healthcare providers.
Many clinicians evaluating biologic therapies look for product safety, consistency, documentation, and traceability. Asking questions about these areas may help patients better understand the options being presented.[5]
Mandatory Safety and Content Testing
Once laboratory credibility is verified, focus shifts to the product testing. Because biologic products can vary significantly, many clinicians review supporting documentation and testing data when evaluating product quality and consistency. Patients should ask their clinician for the specific lab reports tied to the therapy they are considering.
A high-quality biological therapy includes documented proof of comprehensive safety testing. This involves communicable disease and endotoxin testing to confirm the product is free of harmful biological contaminants. Furthermore, patients should specifically request a 14-day sterility test. During this process, the product sits in an incubator for two weeks; if the sample is pure, no bacteria or mold will grow. Some clinicians may review sterility testing documentation as part of their overall product evaluation process.[1, 3]
Safety covers only half the equation; patients must also confirm the actual contents. Many products claim to contain hundreds of healing proteins but lack the data to back it up. Patients may wish to ask whether third-party PCR (Polymerase Chain Reaction) and proteomic studies. These advanced tests identify and quantify the proteins, cytokines, and growth factors present in the vial, providing greater transparency into its biological composition.[4]
The final step in verifying a regenerative therapy happens right before application. Patients should always ask to see the physical packaging or labeling of the product.
Medical products require precise tracking and dosing information. If a regenerative product lacks milligram concentrations on its label, the clinician cannot know the exact dose of signaling proteins they are delivering to the targeted area. Patients may wish to ask whether the product includes lot numbers, QC identification numbers, Donor tracking information, manufacturing documentation, and independent testing reports. These records help establish traceability throughout the manufacturing process and allow physicians to verify the specific product being administered.[2]
Products that do not include clear labeling, traceability information, or supporting documentation may prompt additional questions regarding sourcing, testing, and manufacturing standards.
Conclusion
As regenerative medicine continues to evolve, transparency, documentation, and informed discussions between patients and healthcare providers remain important considerations. Patients have the right to demand explicit proof of safety, sterility, and protein content before agreeing to any biological therapy. By insisting on CLIA-registered third-party testing, verifiable QC tracking, and FDA-registered laboratory standards, consumers protect themselves from unverified claims. Because transparency is critical to patient safety, working closely with a medical professional who prioritizes rigorous, third-party validation ensures that care is guided by clinical evidence rather than commercial promises.[5]
Frequently Asked Questions (FAQs)
Does a higher cost always mean a better regenerative therapy?
Not always. The cost of a therapy should reflect the rigorous laboratory processing, independent third-party testing, and precise scientific quantification behind it. A highly expensive therapy that lacks PCR testing, proteomic data, or CLIA-registered lab reports may not provide the same level of supporting documentation that some clinicians prefer to review. Always base the value of a therapy on the transparency of its documentation.
Why is third-party testing so important?
When a manufacturer tests its own products, there is an inherent risk of bias in how the data is reported. Third-party testing by a CLIA-registered independent laboratory ensures that the safety, sterility, and protein content of the therapy are accurately reported without any conflict of interest.
What should I do if my clinic cannot provide these lab reports?
Product labeling that does not include milligram concentrations, QC identification, or lot numbers—and clinics that do not have third-party PCR and proteomic studies demonstrating the contents of their products—may warrant additional discussion and clarification before proceeding. You have the right to request this documentation before agreeing to any biological therapy.
References
- Buschmann D, et al. Separation, characterization, and standardization of extracellular vesicles for drug delivery applications. Advanced Drug Delivery Reviews. 2021. https://www.sciencedirect.com/science/article/abs/pii/S0169409X21001551 (https://doi.org/10.1016/j.addr.2021.04.027)
- Vermeer NS, et al. Traceability of biologicals: present challenges in pharmacovigilance. Expert Opinion on Drug Safety. 2014. https://www.tandfonline.com/doi/full/10.1517/14740338.2015.972362 (https://doi.org/10.1517/14740338.2015.972362)
- Gandham S, et al. Technologies and Standardization in Research on Extracellular Vesicles. Trends in Biotechnology. 2020. https://www.cell.com/trends/biotechnology/fulltext/S0167-7799(20)30163-3 (https://doi.org/10.1016/j.tibtech.2020.05.012)
- Fan S, Poetsch A. Proteomic Research of Extracellular Vesicles in Clinical Biofluid. Proteomes. 2023. https://www.mdpi.com/2227-7382/11/2/18 (https://doi.org/10.3390/proteomes11020018)
- Chatha PK, et al. Orthobiologics: Current Evidence and What Lies Beyond the Horizon? Seminars in Musculoskeletal Radiology. 2024. https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2724-9777 (https://doi.org/10.1055/a-2724-9777)
